These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 8957670)

  • 21. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
    J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against papillomavirus with a polynucleotide vaccine.
    Donnelly JJ; Martinez D; Jansen KU; Ellis RW; Montgomery DL; Liu MA
    J Infect Dis; 1996 Feb; 173(2):314-20. PubMed ID: 8568291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
    Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
    J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Papillomavirus-like particles and HPV vaccine development.
    Schiller JT; Lowy DR
    Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-papillomavirus vaccines and prevention of cervical cancer: progress and prospects].
    Hantz S; Alain S; Denis F
    Presse Med; 2005 Jun; 34(10):745-53. PubMed ID: 16026130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
    Pastrana DV; Vass WC; Lowy DR; Schiller JT
    Virology; 2001 Jan; 279(1):361-9. PubMed ID: 11145917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
    Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus vaccines.
    Stanley MA
    Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genital human papillomavirus infection.
    Lowy DR; Kirnbauer R; Schiller JT
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2436-40. PubMed ID: 8146136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
    Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
    Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
    Gerber S; Lane C; Brown DM; Lord E; DiLorenzo M; Clements JD; Rybicki E; Williamson AL; Rose RC
    J Virol; 2001 May; 75(10):4752-60. PubMed ID: 11312347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
    Yuan H; Estes PA; Chen Y; Newsome J; Olcese VA; Garcea RL; Schlegel R
    J Virol; 2001 Sep; 75(17):7848-53. PubMed ID: 11483728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine].
    Höpfl R; Heim K
    Hautarzt; 1996 Oct; 47(10):739-43. PubMed ID: 9036120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.